AbbVie Contract Manufacturing offers Hot Melt Extrusion (HME) technology that enhances the bioavailability of poorly soluble APIs. In this on-demand webinar with CMC Lead Sebastien Branchu, PhD, learn about how AbbVie Contract Manufacturing leveraged Hot Melt Extrusion to improve bioavailability, reduce pill burden, and increase shelf life.
A pharmaceutical company launched a first-generation non-HME capsule formulation of a drug with a substantial dose that required storage under refrigeration. The company initiated a partnership with AbbVie CMO with the goal of developing a second-generation amorphous solid dispersion (ASD) tablet formulation. That would allow them to increase both drug load and bioavailability, thus reducing pill burden.
AbbVie applied its stage-based approach to determine the applicability of HME for this poorly soluble drug substance Using Hot Melt Extrusion, AbbVie reformulated the drug with improvements including a 20% reduction in drug dosage, 70% reduced pill burden, doubled shelf life, and more.
Watch our on-demand Hot Melt Extrusion Case Study webinar now to learn about how we improved patient experience across multiple dimensions with this second-generation HME tablet formulation, with details on every stage from Formulation Development to Commercial Manufacturing.